Items Tagged ‘Nerlynx’

July 18th, 2017

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer


The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of Nerlynx following adjuvant trastuzumab treatment. Women (n=2,840) with early-stage HER2-positive breast cancer […]

View full entry

Tags: Breast Cancer, HER2, neratinib, Nerlynx, News